By KATIE THOMAS
The New York Times
Published: July 30, 2013
The drug maker Pfizer agreed to pay $491 million to settle criminal and civil charges over the illegal marketing of the kidney-transplant drug Rapamune, the Justice Department announced on Tuesday.
The settlement is the latest in a string of big-money cases involving the sales practices of major pharmaceutical companies; four years ago, Pfizer paid $2.3 billion for improperly marketing several drugs. The recent case centers on the practices of Wyeth Pharmaceuticals, which Pfizer acquired in 2009.
The entire story is here.
